MANA Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

MANA Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-9,252	Closed	-$825K	–	212
2017 Q4	$825K	Buy	+9,252	New	+$804K	0.35%	97

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MANA Advisors's BMRN Position: Q1 2018 in Review

MANA Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2018, closing a stake of 9,252 shares — an estimated $825K sold.

MANA Advisors first reported a position in BMRN in Q4 2017 and held it in 1 quarter. The position peaked at $825K in Q4 2017. 429 funds tracked by Wall St. Rank hold BMRN as of Q1 2018.

MANA Advisors reported no remaining BioMarin Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
MANA Advisors sold 9,252 BioMarin Pharmaceuticals shares in Q1 2018, an estimated $825K.
MANA Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2017 and held it in 1 quarter.
MANA Advisors's BioMarin Pharmaceuticals position peaked at $825K in Q4 2017.
429 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2018.

Based on MANA Advisors's 13F filing for Q1 2018, filed 15 May 2018.